Read the original post:
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early...
See the article here:
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
See more here:
Better Choice Company To Effectuate a Reverse Stock Split
Originally posted here:
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
See original here:
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024